Pituitary adenoma…nomen omen?
Acromegaly
Cushing disease
Neuroendocrine tumor
Pituitary adenoma
Pituitary pathology
Prolactinoma
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
07
05
2021
accepted:
31
05
2021
pubmed:
12
6
2021
medline:
26
10
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
In 2017, the International Pituitary Pathology Club proposed to rename pituitary adenoma as pituitary neuroendocrine tumors (PitNETs) but since no consensus on this new terminology was obtained the Pituitary Society decided to host on this topic an international multidisciplinary virtual workshop, Pituitary Neoplasm Nomenclature (PANOMEN), to which several Societies participated with the designation of their representatives in the expert panel. Main conclusion of the meeting was that there was not yet a case for adopting the PitNET nomenclature and main recommendation was that the term adenoma is retained. Aim of this Editorial is to comment the outcome of the recently published document of the meeting. Ideally, only the combination of pathological, neuroradiological, and clinical data can define the degree of agressiveness/invasion of a pituitary adenoma and effectively guide treament. This may be classically obtained only with a close multisciplinary collaboration into a PTCOE. It is proposed that improved definition of "invasive" and "aggressive" neoplasms may represent the most clinically effective development in the clinico-neuroradiological-pathological denomination and classification of pituitary adenomas.
Sections du résumé
BACKGROUND
In 2017, the International Pituitary Pathology Club proposed to rename pituitary adenoma as pituitary neuroendocrine tumors (PitNETs) but since no consensus on this new terminology was obtained the Pituitary Society decided to host on this topic an international multidisciplinary virtual workshop, Pituitary Neoplasm Nomenclature (PANOMEN), to which several Societies participated with the designation of their representatives in the expert panel. Main conclusion of the meeting was that there was not yet a case for adopting the PitNET nomenclature and main recommendation was that the term adenoma is retained.
AIM
Aim of this Editorial is to comment the outcome of the recently published document of the meeting.
CONCLUSIONS
Ideally, only the combination of pathological, neuroradiological, and clinical data can define the degree of agressiveness/invasion of a pituitary adenoma and effectively guide treament. This may be classically obtained only with a close multisciplinary collaboration into a PTCOE. It is proposed that improved definition of "invasive" and "aggressive" neoplasms may represent the most clinically effective development in the clinico-neuroradiological-pathological denomination and classification of pituitary adenomas.
Identifiants
pubmed: 34114192
doi: 10.1007/s12020-021-02785-z
pii: 10.1007/s12020-021-02785-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-4Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
M.B.S. Lopes, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 134, 521–535 (2017)
doi: 10.1007/s00401-017-1769-8
S.L. Asa, O. Casar-Borota, P. Chanson, E. Delgrange, P. Earls, S. Ezzat, A. Grossman, H. Ikeda, N. Inoshita, N. Karavitaki, M. Korbonits, E.R. Laws Jr., M.B. Lopes, N. Maartens, I.E. McCutcheon, O. Mete, H. Nishioka, G. Raverot, F. Roncaroli, W. Saeger, L.V. Syro, A. Vasiljevic, C. Villa, A. Wierinckx, J. Trouillas, From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer 24, C5–C8 (2017). attendees of 14th Meeting of the International Pituitary Pathology Club AFN
doi: 10.1530/ERC-17-0004
K.K.Y. Ho, M. Fleseriu, J. Wass, A. van der Lely, A. Barkan, A. Giustina, F.F. Casanueva, A.P. Heaney, N. Biermasz, C. Strasburger, S. Melmed, A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary 22, 569–573 (2019)
doi: 10.1007/s11102-019-00988-2
S.L. Asa, S. Asioli, S. Bozkurt, O. Casar-Borota, L. Chinezu, N. Comunoglu, G. Cossu, M. Cusimano, E. Delgrange, P. Earls, S. Ezzat, N. Gazioglu, A. Grossman, F. Guaraldi, R.A. Hickman, H. Ikeda, M.L. Jaffrain-Rea, N. Karavitaki, I. Kraljevic, S. La Rosa, E. Manojlovic-Gacic, N. Maartens, I.E. McCutcheon, M. Messerer, O. Mete, H. Nishioka, B. Oz, S. Pakbaz, M. Pekmezci, A. Perry, L. Reiniger, F. Roncaroli, W. Saeger, F. Soylemezoglu, O. Tachibana, J. Trouillas, J. Turchini, S. Uccella, C. Villa, S. Yamada, S. Yarman, Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary 23, 322–325 (2020)
doi: 10.1007/s11102-019-01015-0
K.K.Y. Ho, M. Fleseriu, J. Wass, A. van der Lely, A. Barkan, A. Giustina, F.F. Casanueva, A.P. Heaney, N. Biermasz, C. Strasburger, S. Melmed, The tale in evolution: clarity, 21 consistency and consultation, not contradiction and confusion. Pituitary 23, 476–477 (2020)
doi: 10.1007/s11102-019-01027-w
K. Ho, M. Fleseriu, U. Kaiser, R. Salvatori, T. Brue, M.B. Lopes, P. Kunz, M. Molitch, S.A. Camper, M. Gadelha, L.V. Syro, E. Laws, M. Reincke, H. Nishioka, A. Grossman, A. Barkan, F. Casanueva, J. Wass, A. Mamelak, L. Katznelson, A.J. van der Lely, S. Radovick, M. Bidlingmaier, M. Boguszewski, J. Bollerslev, A.R. Hoffman, N. Oyesiku, G. Raverot, A. Ben-Shlomo, R. Fowkes, I. Shimon, H. Fukuoka, A.M. Pereira, Y. Greenman, A.P. Heaney, M. Gurnell, G. Johannsson, R.Y. Osamura, M. Buchfelder, M.C. Zatelli, M. Korbonits, P. Chanson, N. Biermasz, D.R. Clemmons, N. Karavitaki, M.D. Bronstein, P. Trainer, S. Melmed, Pituitary Neoplasm Nomenclature Workshop: does adenoma stand the test of time? J. Endocr. Soc. 5(3), bvaa205 (2021). https://doi.org/10.1210/jendso/bvaa205
doi: 10.1210/jendso/bvaa205
pubmed: 33604494
pmcid: 7874572
A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M.D. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A.M. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A.P. Heaney, K.K.Y. Ho, A.G. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A.M. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S.L. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M.L. Vance, J. Wass, M.E. Wierman, K.C.J. Yuen, M.C. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667–678 (2020). https://doi.org/10.1007/s11154-020-09588-z
doi: 10.1007/s11154-020-09588-z
pubmed: 32914330
pmcid: 7942783
A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, M. Bolanowski, V. Bonert, M.D. Bronstein, F.F. Casanueva, D. Clemmons, A. Colao, D. Ferone, M. Fleseriu, S. Frara, M.R. Gadelha, E. Ghigo, M. Gurnell, A.P. Heaney, K. Ho, A. Ioachimescu, L. Katznelson, F. Kelestimur, J. Kopchick, M. Krsek, S. Lamberts, M. Losa, A. Luger, P. Maffei, M. Marazuela, G. Mazziotti, M. Mercado, P. Mortini, S. Neggers, A.M. Pereira, S. Petersenn, M. Puig-Domingo, R. Salvatori, I. Shimon, C. Strasburger, S. Tsagarakis, A.J. van der Lely, J. Wass, M.C. Zatelli, S. Melmed, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), dgz096 (2020). https://doi.org/10.1210/clinem/dgz096
doi: 10.1210/clinem/dgz096
pubmed: 31606735
P. Mortini, G. Nocera, F. Roncelli, M. Losa, A.M. Formenti, A. Giustina, The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): a surgical perspective. Rev. Endocr. Metab. Disord. 21(4), 527–536 (2020). https://doi.org/10.1007/s11154-020-09564-7
doi: 10.1007/s11154-020-09564-7
pubmed: 32488741
T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37(1), 67–99, viii (2008). https://doi.org/10.1016/j.ecl.2007.10.013
doi: 10.1016/j.ecl.2007.10.013
pubmed: 18226731
S. Frara, G. Rodriguez-Carnero, A.M. Formenti, M.A. Martinez-Olmos, A. Giustina, F.F. Casanueva, Pituitary tumors centers of excellence. Endocrinol. Metab. Clin. North Am. 49(3), 553–564 (2020). https://doi.org/10.1016/j.ecl.2020.05.010
doi: 10.1016/j.ecl.2020.05.010
pubmed: 32741488
S. Melmed, Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937–950 (2020)
doi: 10.1056/NEJMra1810772
A. Giustina, M.D. Bronstein, P. Chanson, S. Petersenn, F.F. Casanueva, C. Sert, A. Houchard, S. Melmed, Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary 22(5), 476–487 (2019). https://doi.org/10.1007/s11102-019-00977-5
doi: 10.1007/s11102-019-00977-5
pubmed: 31338660
pmcid: 6728296
A. Bianchi, A. Giustina, V. Cimino, R. Pola, F. Angelini, A. Pontecorvi, De, L. Marinis, Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J. Clin. Endocrinol. Metab. 94(6), 2015–2022 (2009). https://doi.org/10.1210/jc.2008-1337
doi: 10.1210/jc.2008-1337
pubmed: 19336510
A. Giustina, Acromegalia: ridurre il ritardo della diagnosi [Acromegaly: reducing diagnostic delay]. Recent. Prog. Med. 107(8), 450–451 (2016). https://doi.org/10.1701/2332.25074
doi: 10.1701/2332.25074
S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018). https://doi.org/10.1038/s41574-018-0058-5
doi: 10.1038/s41574-018-0058-5
pubmed: 30050156
pmcid: 7136157
G. Raverot, P. Burman, A. McCormack, A. Heaney, S. Petersenn, V. Popovic, J. Trouillas, O.M. Dekkers, European Society of Endocrinology clinical 26 practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018)
doi: 10.1530/EJE-17-0796
A. Giustina, M.D. Bronstein, F.F. Casanueva, P. Chanson, E. Ghigo, K.K. Ho, A. Klibanski, S. Lamberts, P. Trainer, S. Melmed, Current management practices for acromegaly: an international survey. Pituitary 14(2), 125–133 (2011). https://doi.org/10.1007/s11102-010-0269-9
doi: 10.1007/s11102-010-0269-9
pubmed: 21063787
F.F. Casanueva, A.L. Barkan, M. Buchfelder, A. Klibanski, E.R. Laws, J.S. Loeffler, S. Melmed, P. Mortini, J. Wass, A. Giustina, Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20(5), 489–498 (2017). https://doi.org/10.1007/s11102-017-0838-2
doi: 10.1007/s11102-017-0838-2
pubmed: 28884415
pmcid: 5606938
G. Zada, W.W. Woodmansee, S. Ramkissoon, J. Amadio, V. Nose, E.R. Laws Jr, Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J. Neurosurg. 114, 336–344 (2011)
doi: 10.3171/2010.8.JNS10290
E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33, 610–618 (1993)
pubmed: 8232800
B.P. Meij, M.B. Lopes, D.B. Ellegala, T.D. Alden, E.R. Laws Jr., The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J. Neurosurg. 96, 195–208 (2002)
doi: 10.3171/jns.2002.96.2.0195
A. Fusco, M.C. Zatelli, A. Bianchi, V. Cimino, L. Tilaro, F. Veltri, F. Angelini, L. Lauriola, V. Vellone, F. Doglietto, M.R. Ambrosio, G. Maira, A. Giustina, E.C. degli Uberti, A. Pontecorvi, L. De Marinis, Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 93(7), 2746–2750 (2008). https://doi.org/10.1210/jc.2008-0126
doi: 10.1210/jc.2008-0126
pubmed: 18460561
S. Chiloiro, A. Giampietro, F. Mirra, F. Donfrancesco, T. Tartaglione, P.P. Mattogno, F. Angelini, L. Liverana, M. Gessi, A. Carmelo, G. Rindi, A. Giustina, M. Fleseriu, A. Pontecorvi, L. De Marinis, Bianchi A. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184(2), 217–229 (2021). https://doi.org/10.1530/EJE-20-0767
doi: 10.1530/EJE-20-0767
pubmed: 33136550
S. Frara, A. Allora, L. Castellino, L. di Filippo, P. Loli, A. Giustina, COVID-19 and the pituitary. Pituitary 24(3), 465–481 (2021). https://doi.org/10.1007/s11102-021-01148-1
doi: 10.1007/s11102-021-01148-1
pubmed: 33939057
A. Giustina, E. Legg, B.M. Cesana, S. Frara, P. Mortini, M. Fleseriu,, Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. Endocrine 71(2), 273–280 (2021). https://doi.org/10.1007/s12020-020-02565-1 . Erratum in: Endocrine. 2021 May;72(2):596
M. Puig-Domingo, M. Marazuela, B.O. Yildiz, A. Giustina, COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72(2), 301–316 (2021). https://doi.org/10.1007/s12020-021-02734-w
doi: 10.1007/s12020-021-02734-w
pubmed: 33963516
G. Mazziotti, A. Mosca, S. Frara, G. Vitale, A. Giustina, Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Exp. Opin. Pharmacother. 18(16), 1679–1689 (2017). https://doi.org/10.1080/14656566.2017.1391217
doi: 10.1080/14656566.2017.1391217
M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29(1), 86–93 (2006). https://doi.org/10.1007/BF03349183
doi: 10.1007/BF03349183
pubmed: 16553040
A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5), e36411 (2012). https://doi.org/10.1371/journal.pone.0036411
doi: 10.1371/journal.pone.0036411
pubmed: 22574156
pmcid: 3344864
J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot, A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126, 123–135 (2013)
doi: 10.1007/s00401-013-1084-y
S. Asioli, A. Righi, M. Iommi, C. Baldovini, F. Ambrosi, F. Guaraldi, M. Zoli, D. Mazzatenta, M. Faustini-Fustini, P. Rucci, C. Giannini, M.P. Foschini, Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur. J. Endocrinol. 180, 127–134 (2019)
doi: 10.1530/EJE-18-0749
Chiloiro S., De Marinis L. From pituitary adenoma to pituitary neuroendocrine tumors: how molecular pathways may impact on the therapeutic management? Endocr., Metab. Immune Disord.—Drug Targets. https://doi.org/10.2174/1871530321666210226152901